

12th International Conference on

Allergy, Asthma & Clinical Immunology

October 01-02, 2018 | Moscow, Russia



Glady Gilbert

European Bio Immune(G)ene Medicine Association, France

A sublingual immuno-nanotherapy related to the pathophysiological mechanisms of asthma

For a very long time, it has been customary in medicine to treat diseases by opposing the effects of certain cells or molecules whose disruption is directly involved in the evolutionary course of a disease. The therapeutic results have not always been up to expectations, and the deleterious effects on the other hand often beyond expectations. Besides, these often disappointing results have resulted from very expensive investments. Allergic asthma is one of these diseases, where progress in terms of treatment is not up to the hopes raised by the many basic research works published in recent years and illuminating many physiopathological mechanisms very accurately. The fault probably lies in the absence of a global vision to address the disease at multiple levels of dysfunction at the same time, with the aim to implement a multifocal regulation based on the main pathogenic mechanisms at the origin of asthma. We have developed in recent years a nanotherapy method called Bio Immune(G)ene Medicine (BI(G)MED), allowing a fine regulation of this type of allergic diseases by using first and foremost a biomimetic and holistic approach, devoid of any additional adverse effects.

Biography

Glady Gilbert has graduated Medical School in 1977. Through his work and encounters, he then developed interest and expertise in immunology and immunogenetics that lead him to nanomedicine and nanobiotechnology. He thus became in 2010 the creator of the Bio Immune(G)ene Medicine and Director of EBMA, the European association responsible for communication and trainings in this field. He has participated in numerous international congresses in immuno-allergy, infectiology and oncology and is the author of several publications on nano-biotherapy in different journals.

info@ebma-europe.com

Notes: